Search Results - "Huberman, Mark S"

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma by Rangachari, Deepa, VanderLaan, Paul A, Shea, Meghan, Le, Xiuning, Huberman, Mark S, Kobayashi, Susumu S, Costa, Daniel B

“…Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor…”
Get more information

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer by Yasuda, Hiroyuki, Park, Eunyoung, Yun, Cai-Hong, Sng, Natasha J, Lucena-Araujo, Antonio R, Yeo, Wee-Lee, Huberman, Mark S, Cohen, David W, Nakayama, Sohei, Ishioka, Kota, Yamaguchi, Norihiro, Hanna, Megan, Oxnard, Geoffrey R, Lathan, Christopher S, Moran, Teresa, Sequist, Lecia V, Chaft, Jamie E, Riely, Gregory J, Arcila, Maria E, Soo, Ross A, Meyerson, Matthew, Eck, Michael J, Kobayashi, Susumu S, Costa, Daniel B

“…Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine…”
Get more information

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas by Jorge, Susan E, Lucena-Araujo, Antonio R, Yasuda, Hiroyuki, Piotrowska, Zofia, Oxnard, Geoffrey R, Rangachari, Deepa, Huberman, Mark S, Sequist, Lecia V, Kobayashi, Susumu S, Costa, Daniel B

“…exon 20 insertions account for up to 10% of all mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of…”
Get full text

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors by Kobayashi, Susumu, Canepa, Hannah M, Bailey, Alexandra S, Nakayama, Sohei, Yamaguchi, Norihiro, Goldstein, Michael A, Huberman, Mark S, Costa, Daniel B

“…Non-small-cell lung cancers (NSCLCs) containing EGFR mutations are exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors…”
Get more information

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations by Costa, Daniel B, Halmos, Balázs, Kumar, Amit, Schumer, Susan T, Huberman, Mark S, Boggon, Titus J, Tenen, Daniel G, Kobayashi, Susumu

“…Epidermal growth factor receptor (EGFR) mutations are present in the majority of patients with non-small cell lung cancer (NSCLC) responsive to the EGFR…”
Get full text

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib by Jackman, David M, Yeap, Beow Y, Sequist, Lecia V, Lindeman, Neal, Holmes, Alison J, Joshi, Victoria A, Bell, Daphne W, Huberman, Mark S, Halmos, Balazs, Rabin, Michael S, Haber, Daniel A, Lynch, Thomas J, Meyerson, Matthew, Johnson, Bruce E, Jänne, Pasi A

“…Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non–small cell lung cancer (NSCLC) and are…”
Get full text

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers by Costa, Daniel B, Kobayashi, Susumu, Tenen, Daniel G, Huberman, Mark S

“…Summary Purpose Epidermal growth factor receptor (EGFR) mutations have been found in the majority of gefitinib-responsive non-small cell lung cancer (NSCLC)…”
Get full text

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib by COSTA, Daniel B, NGUYEN, Kim-Son H, HUBERMAN, Mark S, PAO, William, TENEN, Daniel G, KOBAYASHI, Susumu, CHO, Byoung C, SEQUIST, Lecia V, JACKMAN, David M, RIELY, Gregory J, YEAP, Beow Y, HALMOS, Balazs, KIM, Joo H, JÄNNE, Pasi A

“…Purpose: Most lung cancers with activating epidermal growth factor receptor ( EGFR ) mutations respond to gefitinib; however, resistance to this tyrosine…”
Get full text

EGFR testing in advanced non-small-cell lung cancer, a mini-review by Sheikine, Yuri, MD, PhD, Rangachari, Deepa, MD, McDonald, Danielle C., NP, Huberman, Mark S., MD, Folch, Erik S., MD, MSc, VanderLaan, Paul A., MD, PhD, Costa, Daniel B., MD, PhD

“…Abstract Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor ( EGFR )…”
Get full text

Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer by Folch, Erik, Yamaguchi, Norihiro, VanderLaan, Paul A, Kocher, Olivier N, Boucher, David H, Goldstein, Michael A, Huberman, Mark S, Kent, Michael S, Gangadharan, Sidharta P, Costa, Daniel B, Majid, Adnan

“…Adequate tumor acquisition is essential to identify somatic molecular alterations in non-small-cell lung cancer (NSCLC), such as epidermal growth factor…”
Get more information

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors by Le, Xiuning, Desai, Neelam V, Majid, Adnan, Karp, Rebecca S, Huberman, Mark S, Rangachari, Deepa, Kent, Michael S, Gangadharan, Sidharta P, Folch, Erik, VanderLaan, Paul A, Costa, Daniel B

“…Highlights • EGFR mutations occur in some high-grade neuroendocrine lung cancers. • EGFR protein is not expressed in EGFR mutated neuroendocrine lung cancers…”
Get full text

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice by Yamaguchi, Norihiro, VanderLaan, Paul A, Folch, Erik, Boucher, David H, Canepa, Hannah M, Kent, Michael S, Gangadharan, Sidharta P, Majid, Adnan, Kocher, Olivier N, Goldstein, Michael A, Huberman, Mark S, Costa, Daniel B

“…Abstract Introduction The identification of somatic genomic aberrations in non-small-cell lung cancer (NSCLC) is part of evidence-based practice guidelines for…”
Get full text

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers by Rangachari, Deepa, Yamaguchi, Norihiro, VanderLaan, Paul A, Folch, Erik, Mahadevan, Anand, Floyd, Scott R, Uhlmann, Erik J, Wong, Eric T, Dahlberg, Suzanne E, Huberman, Mark S, Costa, Daniel B

“…Highlights • Brain metastases are frequent in ALK rearranged lung cancers. • Brain metastases are frequent in EGFR mutated lung cancers. • ∼25% of patients at…”
Get full text

Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes by VanderLaan, Paul A, Rangachari, Deepa, Mockus, Susan M, Spotlow, Vanessa, Reddi, Honey V, Malcolm, Joan, Huberman, Mark S, Joseph, Loren J, Kobayashi, Susumu S, Costa, Daniel B

“…Highlights • EGFR mutations are identified concurrently with other genomic events. • The impact of concurrent mutations ( TP53 , PIK3CA , PTEN etc) on…”
Get full text

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer by Ostios-Garcia, Lorena, Faig, Jennifer, Leonardi, Giulia C, Adeni, Anika E, Subegdjo, Safiya J, Lydon, Christine A, Rangachari, Deepa, Huberman, Mark S, Sehgal, Kartik, Shea, Meghan, VanderLaan, Paul A, Cheng, Matthew P, Marty, Francisco M, Hammond, Sarah P, Costa, Daniel B, Awad, Mark M

“…Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with NSCLC, little is known about the safety and…”
Get more information

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation by Jorge, Susan E, Schulman, Sol, Freed, Jason A, VanderLaan, Paul A, Rangachari, Deepa, Kobayashi, Susumu S, Huberman, Mark S, Costa, Daniel B

“…Highlights • MET amplification and MET exon 14 skipping mutation happen in lung adenocarcinomas. • These genomic changes predict for response to the…”
Get full text

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer by VanderLaan, Paul A, Yamaguchi, Norihiro, Folch, Erik, Boucher, David H, Kent, Michael S, Gangadharan, Sidharta P, Majid, Adnan, Goldstein, Michael A, Huberman, Mark S, Kocher, Olivier N, Costa, Daniel B

“…Abstract Introduction Identification of some somatic molecular alterations in non-small-cell lung cancer (NSCLC) has become evidence-based practice. The…”
Get full text

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma by Shea, Meghan, Huberman, Mark S, Costa, Daniel B

Get more information

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer by Sehgal, Kartik, Bulumulle, Anushi, Brody, Heather, Gill, Ritu R., Macherla, Shravanti, Qilleri, Aleksandra, McDonald, Danielle C., Cherry, Cynthia R., Shea, Meghan, Huberman, Mark S., VanderLaan, Paul A., Weiss, Glen J., Walker, Paul R., Costa, Daniel B., Rangachari, Deepa

“…Besides modeling/simulation-based analysis, no post-approval studies have evaluated the optimal administration frequency of pembrolizumab in non–small-cell…”
Get full text

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas by Jorge, Susan E, Lucena-Araujo, Antonio R, Yasuda, Hiroyuki, Piotrowska, Zofia, Oxnard, Geoffrey R, Rangachari, Deepa, Huberman, Mark S, Sequist, Lecia V, Kobayashi, Susumu S, Costa, Daniel B

Get full text